Aristeia Capital’s Drugs Made In America Acquisition Corp Rights DMAAR Stock Holding History

Aristeia Capital’s Portfolio DMAAR Stock Details DMAAR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-264,168	Closed	-$16K	–	903
2026 Q1	$16K	Sell	264,168 -617,548	-70%	-$65.4K	﹤0.01%	654
2025 Q4	$165K	Hold	881,716	–	–	﹤0.01%	432
2025 Q3	$192K	Sell	881,716 -6,118	-0.7%	-$1.14K	﹤0.01%	389
2025 Q2	$107K	Sell	887,834 -12,166	-1%	-$1.56K	﹤0.01%	387
2025 Q1	$117K	Buy	+900,000	New	+$126K	﹤0.01%	335

Other funds holding DMAAR

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return

Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return

Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

HCM

Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return

RCM

Rivernorth Capital Management West Palm Beach, Florida $2.1B AUM 2.15% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

AGM

Alpine Global Management New York $615M AUM 34.28% 1-Year Est. Return

Aristeia Capital's DMAAR Position: Q2 2026 in Review

Aristeia Capital sold out of Drugs Made In America Acquisition Corp Rights (DMAAR) in Q2 2026, closing a stake of 264,168 shares — an estimated $16K sold.

Aristeia Capital first reported a position in DMAAR in Q1 2025 and held it in 5 quarters. The position peaked at $192K in Q3 2025. 28 funds tracked by Wall St. Rank hold DMAAR as of Q2 2026.

Aristeia Capital reported no remaining Drugs Made In America Acquisition Corp Rights position as of Q2 2026 after selling out during the quarter.
Aristeia Capital sold 264,168 Drugs Made In America Acquisition Corp Rights shares in Q2 2026, an estimated $16K.
Aristeia Capital first reported a position in Drugs Made In America Acquisition Corp Rights in Q1 2025 and held it in 5 quarters.
Aristeia Capital's Drugs Made In America Acquisition Corp Rights position peaked at $192K in Q3 2025.
28 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp Rights as of Q2 2026.

Based on Aristeia Capital's 13F filing for Q2 2026, filed 14 Aug 2026.